Schizophrenia/Psychosis

It is time for gender-sensitive first-episode psychosis services.

Researchers performed a nationwide register-based study of primary antipsychotic nonadherence in schizophrenia.

The experts weighed in on a wide variety of psychiatric issues for the June 2022 issue of Psychiatric Times.

All mental health clinicians must now develop skills in cultural competence to avoid perpetuating disparities in health outcomes for BIPOC individuals with serious mental illnesses.

Over the past 6 months, Psychiatric Times has featured expert opinions on important psychiatric issues from psychosis to psychedelics.

Does the “early bird get the worm”? Researchers investigated long-term outcomes with an early-switch long-acting injectable antipsychotic in patients with schizophrenia using a population-based cohort.

Interim study results show 77% treatment response rate among participants.

Postpartum psychosis is experienced by 1 to 2 women every 1000 deliveries.

Sociocultural factors have been shown to impact both the presentation and course of schizophrenia/psychosis. Learn more here.

Researchers investigated population-level phenotypes occurring before and after diagnosis of schizophrenia using a large health insurance claims dataset.

In this Special Report, clearly delineate the clinical context of selective psychoses.

What are the benefits of early and comprehensive intervention for patients in their first episode of a serious mental illness?

"This pandemic represents an unprecedented time that requires a psychiatrist’s vigilance in identifying patients at risk for COVID-19–induced psychosis."

“In the general population, insomnia is associated with greater cognitive impairment, but its association (and potential sexual dimorphic effect) in schizophrenia is less clear.”

How do we find the right treatments for our patients with schizophrenia at every step of their journey?

A recent study examined hyperprolactinemia and antipsychotic therapy in patients with schizophrenia and Hashimoto's thyroiditis.

Evidence review focuses on bipolar disorder, psychosis, and major depression.

How can looking at the suffering of patients with schizophrenia through a psychodynamic lens help clinicians develop effective interventions and treatment plans?

The FDA has approved dexmedetomidine sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Predicting mania versus psychosis: Researchers performed a retrospective study of prodromal symptoms, risk factors, and vulnerability markers in first-episode mania and psychosis.

Patients with bipolar I disorder and other mental illnesses may be at increased risk for COVID-19 infection.

Are you taking your medication? Researchers performed a nationwide register-based study of primary antipsychotic nonadherence in schizophrenia.

Findings from a recent study can help clinicians optimize antipsychotic dosing during acute illness exacerbations.

In this CME article, familiarize yourself with various pharmacokinetic, pharmacodynamic, and patient-specific factors to review to develop a successful cross-titration plan from one antipsychotic to another.

A new meta-analysis identifies target for improved care in patients with schizophrenia.

Thinking about sex and sleep in schizophrenia: Researchers performed a large cross-sectional study of sex differences in insomnia and cognition in chronic schizophrenia.

Have you had difficulty with differential diagnosis when patients have manic symptoms and psychosis? One doctor discusses the related DSM-5 criteria changes and some of their implications for psychopharmacology.

The glass is half full: reflections on where we are and hope for where we are heading in psychiatry.

The supplemental new drug application of brexpiprazole for the treatment of schizophrenia in pediatric patients aged 13 to 17 received FDA approval.